251. Impact of wound management strategies after revascularization for chronic limb-threatening ischemia.
- Author
-
Shintani T, Obara H, Matsubara K, Hayashi M, Kita H, Ono S, Watada S, Kikuchi N, Sekimoto Y, Torizaki Y, Asami A, Fujii T, Hayashi K, Harada H, Fujimura N, Hosokawa K, Nakatani E, and Kitagawa Y
- Subjects
- Humans, Chronic Limb-Threatening Ischemia, Retrospective Studies, Treatment Outcome, Risk Factors, Ischemia diagnostic imaging, Ischemia surgery, Limb Salvage adverse effects, Chronic Disease, Osteomyelitis, Peripheral Arterial Disease, Endovascular Procedures adverse effects
- Abstract
Objective: There is no established consensus or guidelines for wound management after revascularization for patients with chronic limb-threatening ischemia (CLTI) without severe infection. This study is designed to evaluate the clinical effect of the wound management strategy on toe wounds after revascularization for CLTI., Methods: This retrospective cohort study was performed at eight institutions affiliated with Keio University School of Medicine in Japan and included 261 patients who underwent revascularization for CLTI between April 2019 and July 2021. We identified 132 patients with toe wounds from the database who had restored in-line blood flow to the foot. Patients were divided into two groups by the timing of toe resection after revascularization, which dictated the wound management policy. Group A (62 patients) underwent early toe amputation for suspected osteomyelitis, whereas group B (70 patients) underwent watchful waiting. The primary outcome was wound healing after revascularization; the secondary outcome was major amputation. We compared outcomes between groups A and B after propensity score matching., Results: Using propensity score matching, each patient in group A (33 patients) was matched with a patient in group B (33 patients). Wound healing in matched group A was significantly better than that in matched group B (respectively: 1-year wound healing rate: 90.0% vs 68.2%, P < .001; median wound healing time: 65 days vs 258 days, P < .01). Although five major amputations were necessary in matched group B, none were required in matched group A (P = .05). The high rate of major amputations in group B was attributed to the sudden exacerbation of infection. Limb salvage rate in matched group A exceeded matched group B (100.0% vs 90.5%: 1-year limb salvage rate, P = .02)., Conclusions: Early toe amputation for highly suspected osteomyelitis in patients with CLTI with toe wounds may expedite wound healing compared with watchful waiting, potentially avoiding unnecessary major amputation. Considering the wound management strategy is crucial when evaluating wound healing outcomes in patients with CLTI with revascularization., Competing Interests: Disclosures N.F. has served as a consultant for Japan Lifeline and Cook Medical. S.O. served as a consultant for Medico’s Hirata. H.O. received educational grant from Cardinal Health, Japan Blood Products Organization, JMS, Taiho Pharmaceutical, Teijin Pharma Limited, MSD, Kaken Pharmaceutical, Sanofi, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma Corporation, Nihon Pharmaceutical, Japan Lifeline, Limfix, Medtronic Japan, Otsuka Pharmaceutical Factory, Daiichi Sankyo Company, Johnson & Johnson, Otsuka Pharmaceutical, Kowa, and W. L. Gore & Associates. Y.K. received lecture fees from Chugai Pharmaceutical, Taiho Pharmaceutical, Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Factory, Ono Pharmaceutical, Shionogi, AstraZeneca, Ethicon, Bristol-Myers Squibb, Olympus Corporation, Cardinal Health, MSD, Smith & Nephew, Kaken Pharmaceutical, Aska Pharmaceutical, Miyarisan Pharmaceutical, Toray Industries, Daiichi Sankyo Company, Chugai Foundation for Innovative Drug Discovery Science, Nippon Kayaku, EA Pharma, Intuitive Surgical, Takeda Pharmaceutical Company Limited, Sysmex Corporation, and Tsumura; and received educational grant from Chugai Pharmaceutical, Taiho Pharmaceutical, Yakult Honsha, Asahi Kasei Pharma, Otsuka Pharmaceutical, Ono Pharmaceutical, Tsumura, Kaken Pharmaceutical, Dainippon Sumitomo Pharma, EA Pharma, Eisai, Otsuka Pharmaceutical Factory, Kyowa Kirin, Takeda Pharmaceutical, Teijin Pharma, Nippon Covidien, Cardinal Health, and Kowa. All other authors declare that they have no relevant conflicts of interest., (Copyright © 2023 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF